Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasm, Residual × Hydroxychloroquine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 7 Colorectal Neoplasms 5 Prostatic Neoplasms 4 Breast Neoplasms 4 Neoplasms 3 COVID-19 3 Ovarian Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Non-Small-Cell Lung 2 Untreated Resectable Pancreatic Adenocarcinoma 1 Sarcoma 1 Rectal Neoplasms 1 Peripheral Nervous System Diseases 1 Pancreatic Cancer Resectable 1 Neoplasm, Residual 1 Lung Neoplasms 1 Liver Neoplasms 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia 1 Klatskin Tumor 1 Hypoxia 1 Hematologic Neoplasms 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Biliary Tract Neoplasms 1 Bile Duct Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

blinatumomab 7 Cyclophosphamide 6 Rituximab 5 Lenalidomide 5 Dexamethasone 5 Azacitidine 5 venetoclax 4 fludarabine 4 fludarabine phosphate 3 Cytarabine 3 tislelizumab 2 thymoglobulin 2 obinutuzumab 2 daratumumab 2 Whole-Body Irradiation 2 N,N-dicyclohexyl-isoborneol-10-sulfonamide 2 Methotrexate 2 Melphalan 2 Immunotherapy 2 Imatinib Mesylate 2 Docetaxel 2 Decitabine 2 Clofarabine 2 Cladribine 2 Calcium Dobesilate 2 Busulfan 2 treosulfan 1 trastuzumab deruxtecan 1 tisagenlecleucel 1 talquetamab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04841148 2025-03-11

PALAVY

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡